Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis
Authors:
- Fumihide OgawaFOFumihide Ogawa
- Yohei IwataYIYohei Iwata
- Kazuhiro KomuraKKKazuhiro Komura
- Eiji MuroiEMEiji Muroi
- Toshihide HaraTHToshihide Hara
- Motoi TakenakaMTMotoi Takenaka
- Kazuhiro ShimizuKSKazuhiro Shimizu
- Minoru HasegawaMHMinoru Hasegawa
- Manabu FujimotoMFManabu Fujimoto
- Shinichi SatoSSShinichi Sato
- 1 January 2009
- journal article
- Published by Taylor & Francis in Autoimmunity
- Vol. 42 (2) , 120-125
Abstract
Systemic sclerosis (SSc) is characterized by immunological abnormalities, especially the production of autoantibodies against various cellular components. Treatment with histone deacetylase (HDAC) inhibitors prevents collagen accumulation in a mouse SSc model. Additionally, autoantibody against HDAC-3 is produced in colon cancer patients, while HDAC-1 and HDAC-2 do not elicit autoantibody response. To determine the presence and levels of antibodies (Abs) against HDAC-3 in SSc. Anti-HDAC-3 Ab was examined by enzyme-linked immunosorbent assay (ELISA) and immunoblotting using human recombinant HDAC-3. The HDAC-3 activity was evaluated by ELISA using the fluorimetric HDAC lysyl substrate that comprises an acetylated lysine side chain. Contrary to our hypothesis that autoimmune background in SSc induced the production of autoantibody against HDACs, IgG and IgM anti-HDAC-3 Ab levels in SSc patients were significantly lower than in normal controls (p < 0.0005 and 0.001, respectively). Furthermore, decreased levels of IgG anti-HDAC-3 Ab were specific to SSc, since IgG anti-HDAC-3 Ab levels in patients with dermatomyositis (DM) and those with systemic lupus erythematosus (SLE) were similar and slightly increased relative to normal controls, respectively. Immunoblotting analysis showed that anti-HDAC-3 Ab was detected in normal controls and patients with DM or SLE, while it was absent in SSc patients. The HDAC-3 activity was significantly inhibited by IgG isolated from sera of normal controls, whereas such inhibitory effect was not observed by IgG isolated from sera of SSc patients. These results indicate the lack of anti-HDAC-3 autoantibody in SSc patients, which is produced in healthy individuals as well as DM and SLE patients, suggesting that this autoantibody might function as protective Ab.This is an electronic version of an article published in Free Radical Research, 42(11-12), 957-965: 2008 November. Free Radical Research is available online at: http://informahealthcare.com/doi/abs/10.1080/0891693080240630Keywords
This publication has 37 references indexed in Scilit:
- Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patientsLupus, 2007
- Histone deacetylase inhibitors decrease Toll‐like receptor‐mediated activation of proinflammatory gene expression by impairing transcription factor recruitmentImmunology, 2007
- Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin‐induced skin fibrosisArthritis & Rheumatism, 2007
- HDAC inhibitors as anti‐inflammatory agentsBritish Journal of Pharmacology, 2007
- Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodentsBritish Journal of Pharmacology, 2007
- Antibody response to a non‐conserved C‐terminal part of human histone deacetylase 3 in colon cancer patientsInternational Journal of Cancer, 2005
- Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical ImplicationMolecular and Cellular Biology, 2005
- Ongoing Immunoglobulin Class Switch DNA Recombination in Lupus B Cells: Analysis of Switch Regulatory RegionsAutoimmunity, 2004
- Function Blocking Autoantibodies Against Matrix Metalloproteinase-1 in Patients with Systemic SclerosisJournal of Investigative Dermatology, 2003
- The mosaic of autoimmunityImmunology Today, 1989